Year: 2022

– Progress includes otenaproxesul’s new formulation, strengthened IP and robust third-party sales projections – Sale of Citagenix subsidiary provides non-dilutive funding – Ended quarter with $45.4 million in cash and equivalents, providing over two years of runway TORONTO, CANADA — (November 15, 2022) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging … Continued

TORONTO, CANADA — (November 2, 2022) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to announce the closing of the sale of its Citagenix Inc. subsidiary to HANSAmed Limited (“HANSAmed”), a leading Canadian distributor of pharmaceuticals and … Continued

– Patent application filed for improved formulation; strengthens IP protection to 2042 – Anticipated benefits include faster onset of action, lower doses – Phase II molar study no longer required; Phase II bunionectomy study on track for H1 2023  TORONTO, CANADA — (October 12, 2022) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage … Continued

– Otenaproxesul demonstrated efficacy in acute pain clinical study conducted in the UK in 2019 Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the selection of a poster presentation of clinical data supporting otenaproxesul’s acute pain … Continued

– Phase II acute pain program to initiate in September – Ended quarter with $50 million in cash and equivalents, providing over two years of runway TORONTO, CANADA — (August 15, 2022) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfideplatform to develop next-generation safer therapies that target … Continued

– Phase II acute pain program to initiate in early calendar Q4 2022 – Ended year with $55 million in cash and equivalents, providing over two years of runway TORONTO, CANADA — (June 30, 2022) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation … Continued

TORONTO, CANADA — (June 15, 2022) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (the “Company”), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, announces that it is extending the expiry date (the “Warrant Extension”) and amending the exercise price (the “Amended Exercise Price”) of 3,117,957 … Continued

TORONTO, CANADA — (May 25, 2022) — Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the appointment of Robert E. Hoffman, a Director of Antibe, as the new Chair of its Board of Directors. The … Continued

– $6.5 million all-cash transaction, including milestone payments – Enables exclusive focus on drug pipeline TORONTO, CANADA — (May 2, 2022) — Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the signing of a binding … Continued

TORONTO, CANADA — (April 25, 2022) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, today announced its participation in the 2022 Bloom Burton & Co. Healthcare Investor Conference being held in person on May 2-3, 2022. Dan Legault, Antibe’s … Continued

– Acute pain clinical program for otenaproxesul initiating this quarter – Ended quarter with a $59 million cash position TORONTO, CANADA — (February 14, 2022) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial and … Continued